Thrombin receptor antagonists
AssigneeSchering Corporation
InventorsSamuel Chackalamannil, Martin Clasby, William Greenlee, Yuguang Wang, Yan Xia, Enrico Veltri, Mariappan Chelliah
Life of this patent
Estimating the term…
Loading patent…
AssigneeSchering Corporation
InventorsSamuel Chackalamannil, Martin Clasby, William Greenlee, Yuguang Wang, Yan Xia, Enrico Veltri, Mariappan Chelliah
Estimating the term…
Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond, n is 0-2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, —OH, (C1-C6)alkoxy, R27-aryl(C1-C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
A compound represented by the structural formula
Dependencies are inferred from the claim text.